Biotech | May 12, 2022
First patient dosed with antiepileptic drug candidate CB03 in a first-in-human Phase I trial
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
“We are committed to making India a global medical value hub by further strengthening our traditional medicine industry and boosting 'Heal in India' & 'Heal by India'
The department will soon release a policy to catalyze research & development and innovation in the pharma- Medtech sector in India
This agreement is truly remarkable for achieving greater objectives in the projects and addressing larger problems
The approved product has a market size of US $ 1172 million for the twelve months ending March 2022, according to IQVIA
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
TSCS appeals to the Govt. of Telangana to release a G.O for mandatory antenatal test - HbA2 for every pregnant woman to help prevent the birth of Thalassemia Major Children for the well-being of their family & Telangana State
The $44 million facility is part of Thermo Fisher's $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19
The data driven fertility company helps increase the success rate of fertility treatments
Through the contract, the company will supply two key GMP intermediates for one of the 'patented drugs' of the innovator pharmaceutical customer
Subscribe To Our Newsletter & Stay Updated
